Reaction
Ileostomy reporting signals
As of the last recalculation, Ileostomy appears in 2,492 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is UPADACITINIB (PRR 33.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Upadacitinib | 288 | 33.2 | 33.3 |
| Vedolizumab | 274 | 29.7 | 29.8 |
| Risankizumab-Rzaa | 252 | 28.5 | 28.6 |
| Infliximab | 444 | 20.4 | 20.5 |
| Infliximab-Dyyb | 62 | 18.1 | 18.2 |
| Ustekinumab | 204 | 18.0 | 18.1 |
| Adalimumab-Fkjp | 90 | 16.8 | 16.8 |
| Azathioprine | 166 | 16.8 | 16.8 |
| Adalimumab-Aaty | 88 | 16.1 | 16.1 |
| Adalimumab-Adaz | 91 | 14.9 | 14.9 |
| Cholestyramine | 14 | 9.7 | 9.7 |
| Adalimumab | 634 | 9.7 | 9.7 |
| Tofacitinib Citrate | 15 | 9.6 | 9.6 |
| Mesalamine | 62 | 9.4 | 9.4 |
| Mercaptopurine | 19 | 9.2 | 9.2 |
| Metronidazole | 68 | 9.1 | 9.1 |
| Niraparib | 23 | 8.7 | 8.7 |
| Diphenoxylate Hydrochloride And Atropine Sulfate | 13 | 8.0 | 8.0 |
| Panitumumab | 11 | 5.9 | 5.9 |
| Loperamide Hydrochloride And Dimethicone | 21 | 5.5 | 5.5 |
| Piperacillin Sodium,Tazobactam Sodium | 16 | 5.1 | 5.1 |
| Teduglutide | 7 | 4.3 | 4.4 |
| Golimumab | 38 | 3.7 | 3.7 |
| Certolizumab Pegol | 47 | 3.4 | 3.4 |
| Glecaprevir And Pibrentasvir | 4 | 3.0 | 3.0 |
| Bosutinib | 3 | 2.8 | 2.8 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 3 | 2.0 | 2.0 |
| Patiromer | 3 | 1.8 | 1.8 |
| Guselkumab | 6 | 1.4 | 1.4 |